Theranos Fraud Timeline: Claims, SEC Action, Trial and Sentencing

The promise and the representation

Theranos promised to transform blood testing with small samples and compact proprietary analyzers. Ambition and future research are not fraud by themselves. The legal problem concerned representations that current technology, deployment and financial performance had reached levels the government said were false. A source-led timeline therefore distinguishes a company’s aspirational mission from specific statements made to investors and partners. It also separates civil enforcement by the Securities and Exchange Commission from criminal prosecution by the Justice Department, because those proceedings used different standards and reached different outcomes.

Sources: U.S. Securities and Exchange Commission · U.S. Securities and Exchange Commission · U.S. Attorney’s Office, Northern District of California

What the SEC alleged in 2018

In March 2018 the SEC charged Theranos, founder Elizabeth Holmes and former president Ramesh ‘Sunny’ Balwani with a years-long fraud that the agency said raised more than $700 million from investors. The complaint described statements in presentations, demonstrations and media coverage that exaggerated or misstated the company’s technology, business relationships and financial performance. Theranos and Holmes agreed to settle without admitting or denying the SEC’s allegations; the agency continued litigation against Balwani. That settlement language must remain attached to the civil stage rather than rewritten as a criminal confession.

Sources: U.S. Securities and Exchange Commission · U.S. Securities and Exchange Commission · U.S. Attorney’s Office, Northern District of California

Technology, deployment and revenue claims

The SEC said Theranos’s proprietary analyzer could perform only a small number of tests and that the company ran most patient testing on modified conventional machines made by others. It also alleged false claims that the technology had been deployed by the Department of Defense in Afghanistan and on medical-evacuation helicopters. Revenue is another example of why exact sourcing matters: the agency contrasted a projection of more than $100 million for 2014 with a little more than $100,000 in operational revenue. These are SEC allegations from the complaint and release, not numbers invented by a retrospective narrator.

Sources: U.S. Securities and Exchange Commission · U.S. Securities and Exchange Commission · U.S. Attorney’s Office, Northern District of California

Civil settlement and separate criminal case

Under the civil settlement, Holmes paid a penalty, surrendered voting control and shares, and accepted a ten-year public-company officer-and-director bar, subject to court approval described in the release. Federal prosecutors separately charged Holmes and Balwani. Criminal juries later returned guilty verdicts on investor-fraud-related counts in separate trials. The split outcomes matter: not every charge produced a conviction, and a civil settlement does not answer a criminal count. A correct timeline records each verdict rather than summarizing the entire history as one undifferentiated finding.

Sources: U.S. Securities and Exchange Commission · U.S. Securities and Exchange Commission · U.S. Attorney’s Office, Northern District of California

Conviction and sentence

Holmes was sentenced in November 2022 to more than eleven years in prison for defrauding investors. Balwani received a separate sentence after his conviction. Sentencing releases summarize the conduct proved and the court’s punishment, but they should be read with verdict forms and judgments when precise counts matter. Patient experiences, laboratory regulation and investor deception overlap in the public story, yet the criminal convictions were tied to particular charged schemes. Naming the victim group and count prevents a broader moral conclusion from becoming an inaccurate legal statement.

Sources: U.S. Securities and Exchange Commission · U.S. Securities and Exchange Commission · U.S. Attorney’s Office, Northern District of California

What the timeline teaches

The timeline’s durable lesson is the difference between secrecy necessary for invention and opacity used to prevent verification. Investors and partners need independent evidence for present capability, not only demonstrations controlled by the company. Boards need technical and regulatory expertise capable of challenging a celebrated founder. Journalists must distinguish access from validation. None of those lessons requires treating every failed startup as fraud. Theranos is instructive because government filings identify specific claims, documentary contrasts and jury findings that cross the line from optimism into deception.

Updates should follow the case dockets, judgments and restitution orders, not prison gossip or dramatized adaptations. A television series can illuminate character and atmosphere, but it does not replace the SEC complaint or criminal record. The page also avoids using a founder’s clothing, voice or personality as proof; visual branding explains attention, not guilt. The evidence is in statements, capabilities, money flows and findings. That approach keeps the story useful after the cultural image of the black turtleneck fades.

Sources: U.S. Securities and Exchange Commission · U.S. Securities and Exchange Commission · U.S. Attorney’s Office, Northern District of California

Questions, answered